Background
obesity, myocardial infarction, cardiovascular disease, left ventricular systolic and diastolic function, Diabetes, heart failure, diabetes
OBESITY, MINERALOCORTICOIDS, MYOCARDIAL INFARCTION, CARDIOVASCULAR DISEASE, EVENT, SECONDARY, DIABETES, HEART FAILURE, TYPE 2 DIABETES, DIABETES
In patients with type 2 diabetes, the risk of heart failure hospitalization as the first cardiovascular event exceeds myocardial infarction by approximately a factor four [Experimental evidence has proven that inhibition of the mineralocorticoid receptor is an important therapeutic target in the prevention of cardiovascular disease in animal models of diabetes, obesity and early heart failure [In this substudy of the Mineralocorticoid Receptor Antagonist in type 2 Diabetes (MIRAD) trial, we aimed to investigate whether high-dose eplerenone as an add-on therapy improves left ventricular function evaluated by echocardiography. In the present study we report the prespecified, secondary endpoints of left ventricular systolic and diastolic function, including global longitudinal strain (GLS), after 26 weeks of treatment with the MRA, eplerenone.